Astellas Initiates Phase 1b Clinical Trial of 'Gilteritinib' for the Treatment of ALK-Positive Non-Small Cell Lung Cancer
A New Approach to Overcoming ALK Inhibitor Resistance
Patients with ALK-positive non-small cell lung cancer (NSCLC) are treated with second-generation drugs such as alectinib or third-generation lorlatinib; however, they eventually develop drug resistance due to additional genetic mutations. New treatment options for patients who have failed existing therapies are a significant unmet medical need in the oncology field. The Phase 1b clinical trial being conducted by Astellas is an attempt to provide a new breakthrough for patients who exhibit resistance to existing standard treatments.
Maximizing Pipeline Value Through Indication Expansion
The key drug in this trial, gilteritinib (Xospata), is an approved drug in the United States by the FDA for the treatment of acute myeloid leukemia (AML) with FLT3 mutations. Based on preclinical research results indicating that gilteritinib has potent inhibitory activity against not only FLT3 but also ALK and AXL kinases, Astellas is pursuing an indication expansion strategy. Utilizing an already approved drug through drug repurposing is an efficient strategy that can significantly reduce development time and costs.
Blocking the AXL Bypass Pathway and the Potential for Treating Brain Metastases
One of the main reasons for resistance in ALK-positive NSCLC patients is the activation of the AXL receptor, which leads to the activation of bypass signaling pathways. Gilteritinib provides a unique mechanism by simultaneously inhibiting both ALK mutations and AXL, thereby blocking the bypass pathways of cancer cells. In particular, a case report showed that gilteritinib demonstrated long-term disease control for more than 24 months in patients with ALK-positive NSCLC with brain metastases, suggesting that its ability to cross the blood-brain barrier (BBB) will also be a very positive evaluation factor in this trial.
Design of the Phase 1b Trial and Future Value Prospects
This Phase 1b trial (2215-CL-5201) will focus on verifying the safety and tolerability of gilteritinib monotherapy in approximately 40 patients and determining the optimal recommended dose. It is designed as a multinational trial, with patients being recruited from major research centers in the United States, France, and Spain. The primary endpoints will be dose-limiting toxicity (DLT) and adverse events (AE). If the trial demonstrates positive safety and preliminary efficacy, it will undoubtedly be an opportunity for Astellas to further expand its presence in the approximately $5.2 billion ALK-positive NSCLC market.
This Phase 1b trial represents Astellas' core strategy to diversify the targets of gilteritinib (Xospata), which has already received FDA approval, to include ALK and AXL, with the aim of significantly expanding its indication to the approximately $5.2 billion ALK-positive NSCLC market. The mechanism of simultaneously inhibiting the bypass pathway (AXL) in patients who have developed resistance to existing standard treatments such as alectinib (Alecensa) or lorlatinib (Lorbrena) has high medical and commercial value. In the short term, the goal is to secure safety and optimal dosage through the Phase 1b trial, and in the medium to long term, it will maximize pipeline value by providing a treatment for highly unmet needs in late-stage patients and patients with brain metastases. In particular, with the development of fourth-generation competing pipelines such as neladalkib from Nuvalent, the addition of an indication to an already approved drug can be a strong competitive advantage in accelerating market entry.
Source: ClinicalTrials.gov (api_ct)